Found 534 hits.
|
209. |
Zuberbier, T.+, Stevanovic, K., Ansotegui, I. J., Anto, J. M., Bergmann, K.-C., D’Amato, G., Grüntuch-Ernst, A., Haahtela, T., Maurer, M., Pietikäinen, S., Christou, D., and Bousquet, J.: Green roof gardens – selecting allergy friendly vegetation: a GA²LEN position paper. J. Allergy Clin. Immunol. Pract. 2023: 12; 347-354. IF: 8.20 |
r.209
|
210. |
Metz, M., Kolkhir, P., Altrichter, S., Siebenhaar, F., Levi-Schaffer, F., Youngblood, B. A., Church, M. K., and Maurer, M.+: Mast cell silencing: a novel therapeutic approach for urticaria and other mast cell-mediated diseases. Allergy 2023: 79; 37-51. IF: 12.60 |
r.210
|
565. |
Zuberbier, T.+, Altrichter, S., Bauer, S., Brehler, R., Brockow, K., Dressler, C., Fluhr, J., Gaskins, M., Hamelmann, E., Kühne, K., Merk, H., Mülleneisen, N. K., Nast, A., Olze, H., Ott, H., Pleimes, M., Ruëff, F., Staubach-Renz, P., Wedi, B., and Maurer, M.: S3-Guideline Urticaria. Part 1: Classification and diagnosis of urticaria – German-language adaptation of the international S3 guideline. J. Dtsch. Dermatol. Ges. 2023: 21; 81-93. IF: 5.50 |
o.565
|
566. |
Zuberbier, T.+, Altrichter, S., Bauer, S., Brehler, R., Brockow, K., Dressler, C., Fluhr, J., Gaskins, M., Hamelmann, E., Kühne, K., Merk, H., Mülleneisen, N. K., Nast, A., Olze, H., Ott, H., Pleimes, M., Ruëff, F., Staubach-Renz, P., Wedi, B., and Maurer, M.: S3-Guideline Urticaria. Part 2: Treatment of urticaria – German-language adaptation of the international S3 guideline. J. Dtsch. Dermatol. Ges. 2023: 21; 202-215. IF: 5.50 |
o.566
|
567. |
Buttgereit, T.*, Nicola, S.*, Vera, C., Brussino, L., Maurer, M.+*, and Magerl, M.*: Significant response to berotralstat in 3 patients with hereditary angioedema of unknown origin. J. Allergy Clin. Immunol. Pract. 2023: 11; 3804-3807. IF: 8.20 |
o.567
|
568. |
Baumann, K., Jørgensen, A. R., Sørensen, J. A., Zhang, D. G., Ghazanfar, M. N., Skov, P. S., Woetmann, A., Vestergaard, C., Maurer, M., and Thomsen, S. F.+: Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria. Clin. Exp. Allergy 2023: 53; 1318-1321. IF: 6.30 |
o.568
|
192. |
Kocatürk, E., Muñoz, M., Elieh-Ali-Komi, D., Criado, P. R., Peter, J., Kolkhir, P., Can, P., Wedi, B., Rudenko, M., Gotua, M., Ensina, L. F., Grattan, C., and Maurer, M.+: How infection and vaccination are linked to acute and chronic urticarial: a special focus on COVID-19. Viruses 2023: 15; 1585. IF: 3.80 |
r.192
|
193. |
Terhorst-Molawi, D., Fox, L., Siebenhaar, F., Metz, M., and Maurer, M.+: Stepping down treatment in chronic spontaneous urticaria – what we know and what we don‘t know. Am. J. Clin. Dermatol. 2023: 24; 397-404. IF: 8.60 |
r.193
|
194. |
McSweeney, S. M.+, Christou, E. A. A., Maurer, M., Grattan, C. E., Tziotzios, C., and McGrath, J. A.: Physical urticaria: clinical features, pathogenesis, diagnostic work-up, and management. J. Am. Acad. Dermatol. 2023: 89; 324-337. IF: 12.80 |
r.194
|
195. |
Kolkhir, P.+, Grad, D. A., Charalampous, P., Cruz Oliveira, C., Mechili, E. A., Unim, B., Pearce, D. A., Maurer, M., Devleesschauwer, B., and Haagsma, J.: An EU task force to assess the burden of rare diseases. Nat. Medicine 2023: 29; 516-517. IF: 58.70 |
r.195